Brief: Pfizer reaches settlement agreements with Dexcel Pharma, Hikma & Cipla for Vyndamax
April 28 (Reuters) - Pfizer Inc PFE.N: PFIZER REACHES THREE SETTLEMENT AGREEMENTS FOR VYNDAMAX PFIZER REACHES THREE SETTLEMENT AGREEMENTS FOR VYNDAMAX PFIZER: SETTLEMENTS EXTEND EFFECTIVE U.S. PATENT EXPIRY DATE FOR VYNDAMAX TO JUNE 1, 2031 PFIZER: AS A RESULT OF SETTLEMENT, REVENUES ARE NOW EXPECTED TO REMAIN RELATIVELY STABLE FROM 2028 THROUGH MID-2031 Source text: ID:nBw7SkPXwa Further company coverage: PFE.N
Recent news on Cipla
See all newsIndian pharma stocks up on report US taps drugmakers for critical cancer drug
India's Cipla jumps after Citi sees near-term positive triggers for earnings
Factbox: Global drugmakers invest billions to boost US presence
India raises price cap on cancer drugs to tackle shortage
Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated